Study Validates JAK Inhibitor for Acute GVHD

]]>(MedPage Today) -- Patients with steroid-refractory graft-versus-host disease (GVHD) after allogeneic stem-cell transplant were almost twice as likely to respond to the Janus kinase (JAK) 1/2 inhibitor ruxolitinib (Jakavi) as compared with standard...